All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
Status | Trial ID | Title | Completion date | Category |
---|---|---|---|---|
Ongoing | 2008-000225-19 | ENSAYO CLÍNICO DE FASE II, MULTICÉNTRICO, ABIERTO, NO CONTROLADO PARA EVALUAR LA EFICACIA DE LA COMBINACIÓN DE SORAFENIB Y BEVACIZUMAB EN EL TRATAMIENTO DE PACIENTES CON TUMOR NEUROENDOCRINO AVANZADO ... | not-yet-due | |
Completed, but no date, and reported results | 2010-020749-28 | Ensayo clínico fase II, abierto, no controlado, multicéntrico de pazopanib en monoterapia para la determinación de actividad, seguridad y biomarcadores predictivos en pacientes con progresión de tumo... | bad-data | |
Completed, but no date, and reported results | 2010-023422-20 | Estudio en fase II de everolimus, un inhibidor mTOR (de formulación oral), junto con OcteotrideLAR®, en pacientes adultos con tumores neuroendocrinos gastrointestinales avanzados no funcionales y bien... | bad-data | |
Listed as ongoing, but also has a completion date | 2011-001550-29 | A Phase II randomized double-blind study of Santostatin LAR in combination with Axitinib versus Placebo in patients with progressive advanced well-differentiated neuroendocrine carcinomas of non-pancr... | 2023-12-31 | bad-data |
Listed as ongoing, but also has a completion date | 2013-000726-66 | Randomized open label study to compare the efficacy and safety of everolimus followed by chemotherapy with STZ-5FU upon progression or the reverse sequence, chemotherapy with STZ-5FU followed by evero... | 2021-07-12 | bad-data |
Ongoing | 2014-003924-34 | A phase II trial to assess the activity and safety of Palbociclib in patients with well- and moderately-differentiated metastatic pancreatic neuroendocrine tumors (pNET). Estudio fase II para evalu... | not-yet-due | |
Reported results | 2014-004072-30 | A phase II trial to assess the activity and safety of TH-302 in combination with sunitinib in patients with well- and moderately-differentiated metastatic pancreatic neuroendocrine tumors (pNET) previ... | 2020-01-10 | due-trials |
Listed as ongoing, but also has a completion date and reported results | 2015-001467-39 | A phase II study to evaluate the safety and efficacy of lenvatinib in patients with advanced grade 1/2 neuroendocrine neoplasmas of pancreatic and extrapancreatic origin. Estudio fase II para evalu... | 2020-08-12 | bad-data |
Reported results | 2015-005774-37 | Phase II study to evaluate efficacy of rechallenge with Sunitinib in Patients with Metastatic Pancreatic Neuroendocrine Tumor (pNETs) well differentiated G1/2 advanced or metastatic who previously fai... | 2019-10-23 | due-trials |
Ongoing, reported early | 2016-002858-20 | A phase II study of durvalumab (MEDI4736) plus tremelimumab for the treatment of patients with advanced neuroendocrine neoplasms of gastroenteropancreatic or lung origin (the DUNE trial). Estudio c... | not-yet-due | |
Ongoing | 2018-001066-42 | A phase II study of durvalumab (MEDI4736) plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma - The DUTHY trial Estudio de fase II de durvalumab ... | not-yet-due | |
Ongoing, reported early | 2019-001546-18 | A phase II study of Platinum-doublet chemotherapy in combination with nivolumab as first-line treatment, in subjects with unresectable, locally advanced or metastatic G3 Neuroendocrine Neoplasms (NENs... | not-yet-due | |
Ongoing | 2022-002419-48 | Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer. Estudio de fase II con biomarcadores de cabozantinib en cáncer de tiroides diferenc... | not-yet-due |